Navigation Links
Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis
Date:11/7/2007

ents' utility scores were estimated and used to calculate QALYs. To determine costs, in addition to the costs of HA, patients who responded to HA treatment were assigned costs of health care utilization attributed to patients without OA, and non-responders were assigned costs of health care resources consumed by OA patients. Cost- effectiveness was expressed as average and incremental cost per QALY.

The responder rate for patients in the HA treatment arm was approximately 83 percent, and the mean QALY gained was 0.0877 for each patient responding to treatment with HA over baseline values. When the change of QALY of the non- responders was set as zero, the HA treatment yielded a cost-utility ratio of $38,964, while that of the control group ranged from $36,077 (assuming a 75 percent response rate) to $139,648 (25 percent response rate).

The study concluded that the cost-utility ratio for EUFLEXXA(TM) is within the range needed to adopt a new technology, and that the product's wider adoption would result in greater savings to the health care system.

About EUFLEXXA(TM)

EUFLEXXA(TM) (1% sodium hyaluronate) is the first and only non-avian derived hyaluronic acid approved in the U.S. for the treatment of pain caused by knee osteoarthritis and is indicated for a three-injection treatment regimen for patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics (eg, acetaminophen). In a prospective, randomized, double-blind, head-to-head study versus the market leading HA therapy, significantly more patients were "pain free" and "symptom free" with EUFLEXXA(TM).(2)

The process used to manufacture EUFLEXXA(TM) produces the HA that most closely resembles the HA in healthy human synovial fluid and the most highly purified HA product available today. In addition, since it is not derived from an avian source (chicken or rooster combs), the risk of reactions related to avian proteins is eliminated.(3-8
'/>"/>

SOURCE Ferring Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)...  IGI Laboratories, Inc. (NYSE-MKT: IG), a New ... presenting today at the Deutsche Bank 40th Annual Health Care ... and 7 th at The InterContinental Hotel, ... , CEO and President and Jenniffer Collins , Chief ... 6, 2015, at 3:30 p.m. ET.   The presentation will ...
(Date:5/6/2015)... LOUIS , May 6, 2015   Sigma-Aldrich Corporation ... and high technology company, today announced a $50,000 product ... a large-scale initiative to replicate key findings from recent ... project is a collaboration between the online research marketplace ... Open Science and the open-access journal eLife. ...
(Date:5/6/2015)...   Symbiomix Therapeutics today announced multiple milestones, ... of a $41 million Series A financing and positive ... a single oral dose of SYM-1219 for the treatment ... U.S. Food and Drug Administration (FDA) at an End-of-Phase ... the Phase 2 trial as one of two pivotal ...
Breaking Medicine Technology:Sigma-Aldrich Donates $50K in Products to the Reproducibility Project to Foster Replicable Research and Accelerate Scientific Discoveries in Cancer Biology 2Sigma-Aldrich Donates $50K in Products to the Reproducibility Project to Foster Replicable Research and Accelerate Scientific Discoveries in Cancer Biology 3Symbiomix Therapeutics Announces Closing of $41M Financing and Positive Results from a Pivotal Phase 2 Trial of SYM-1219 for the Treatment of Bacterial Vaginosis 2Symbiomix Therapeutics Announces Closing of $41M Financing and Positive Results from a Pivotal Phase 2 Trial of SYM-1219 for the Treatment of Bacterial Vaginosis 3Symbiomix Therapeutics Announces Closing of $41M Financing and Positive Results from a Pivotal Phase 2 Trial of SYM-1219 for the Treatment of Bacterial Vaginosis 4Symbiomix Therapeutics Announces Closing of $41M Financing and Positive Results from a Pivotal Phase 2 Trial of SYM-1219 for the Treatment of Bacterial Vaginosis 5
... , March 22 Cambrex Corporation (NYSE: ... GmbH (“IEP”), a privately held company that is a ... located in Wiesbaden, Germany and offers cost ... to the pharmaceutical industry, with the ability to utilize ...
... Ga. , March 22 GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), a biotechnology company that is developing and testing innovative ... serve as its investor relations and public relations agency. , ... , ... ...
Cached Medicine Technology:Cambrex Acquires IEP GmbH 2Cambrex Acquires IEP GmbH 3GeoVax Labs Engages The Investor Relations Group 2GeoVax Labs Engages The Investor Relations Group 3GeoVax Labs Engages The Investor Relations Group 4
(Date:5/6/2015)... May 06, 2015 Healthcare jobs ... mark after launching in mid-February. The company connects hospitals, ... have previous experience in the industry. Likewise, job seekers ... According to Kyle Johnson, CTO, unique traffic to the ... first month: "Each new job posting brings targeted, interested ...
(Date:5/6/2015)... 06, 2015 The 2015 STEMtech conference ... Corporate Partner booth selection . Don’t miss this ... community college and university decision-makers from around the country. ... 2015, at the Arizona Grand in Phoenix. This beautiful ... on the doorstep of the South Mountain Preserve. The ...
(Date:5/6/2015)... May 06, 2015 Topical BioMedics, Inc., announces ... May 12th, from 12pm – 1pm, streamed live and then ... and open to the public by clicking on the following ... attendees are invited “real time” during the webinar, and questions ... , The topic for the May webinar is ...
(Date:5/6/2015)... (PRWEB) May 06, 2015 Cloud security ... today announced a strategic partnership to help small-to-medium businesses ... The two industry-leading companies are teaming up to transition ... , “We’re thrilled to welcome SafeMonk users to ... that the people behind SafeMonk, the global powerhouse SafeNet ...
(Date:5/6/2015)... Arizona (PRWEB) May 06, 2015 ... IMMEDIATE RELEASE , Med Ag Ventures, Inc. (MAV), ... manufacturing capacity of its Arizona based Phoenician Engineering ... grinders last September. MAV recently achieved profitability from ... network expanded from 100 at the end of ...
Breaking Medicine News(10 mins):Health News:Job Seekers Turn to JobMedic to Find Healthcare Positions - JobMedic.com Reaches 1,000 User Milestone 2Health News:STEMtech Conference Exhibitors Gain Access to Community College and University Representatives From Across the U.S. 2Health News:Topical BioMedics Hosts May Pain Management Webinar “What You need to Know about Fibromyalgia” 2Health News:Topical BioMedics Hosts May Pain Management Webinar “What You need to Know about Fibromyalgia” 3Health News:Topical BioMedics Hosts May Pain Management Webinar “What You need to Know about Fibromyalgia” 4Health News:Topical BioMedics Hosts May Pain Management Webinar “What You need to Know about Fibromyalgia” 5Health News:Sookasa Grows Globally With SafeMonk Partnership 2Health News:Sookasa Grows Globally With SafeMonk Partnership 3Health News:Cannibus Industry Start-Up Reaches Profitability While Expanding Its Proprietary Ancillary Medical Marijuana Product IP Portfolio 2
... State University of New Jersey have come up with ... determining the quality of mate in humans.// , ... mates among many animal species. Impressive dancers attract more ... association with computer scientist at the University of Washington ...
... Four women who lost their children in the tsunami last ... that enabled them to conceive again.// , ,Despite having ... Tamil Nadu in southern India will now be able to ... surgery called recanalization. , ,"We cannot get back our ...
... how old they get, never lose their beauty - they merely ... ,Jacqueline Saburido was a very normal girl who was in ... incident that occurred on the 19th of September 1999 changed her ... than 60% of her body was burnt. She lost her ears, ...
... Marie Rogers has won the right to fight for receiving the ... an aggressive type of breast cancer and wants to make sure ... the disease is in its early stage has meant that the ... have already taken legal recourse for the same. Even Patricia Hewitt, ...
... by Dr Michael Fenech studied the damage of excess alcohol on ... excess intake of // alcoholic beverages resulted in increased risk of ... the study, six men aged 21-26 stuck to a diet low ... of either complete red wine, red wine with the alcohol removed ...
... to have been responsible for much of the DNA among ... The tendency of human beings to live in settlements and ... selection process. ,One way to look for ... to study mutations called single-nucleotide polymorphisms (SNPs) - single-letter differences ...
Cached Medicine News:Health News:Recanalization enables Tsunami mourners to parent again 2Health News:The Looming Controversy Surrounding Facial Transplant 2Health News:DNA Underwent Changes Due To Culture 2
Solid 4 mm blades. Locking thumb. Dull finish. Holes in bar decrease weight of speculum....
Open 14 mm blades with 6 mm lifting wings. Dull finish....
Open 10 mm blades. Dull finish....
Open wire style 16 mm blade with a wing tip twist giving the surgeon better on-axis accessibility....
Medicine Products: